|
CRG's
Official Statement on Biopharmaceutical Crops
download
as .pdf
On November 12, newspapers across the
United States reported that the Food and Drug Administration (FDA)
had ordered the destruction of 500,000 biopharmaceutically contaminated
bushels of Nebraska soybeans. One day later, the United States Department
of Agriculture (USDA) admitted to destroying, without informing
the public, 155 acres of similarly contaminated Iowa soybean fields
in September.
These events thrust biopharming, a process
by which plants are genetically modified to produce pharmaceutical
or industrial substances and harvested, into the public spotlight.
Long known mostly to industry insiders, who see it as the future
of biotechnological agriculture, and activists alarmed by the industry's
secretive, poorly regulated practices, biopharming has clearly become
an issue of serious public concern.
Over three hundred USDA-approved open-field
trials of biopharmaceutical crops have been conducted in dozens
of states across the nation. These crops are often wholly experimental,
producing substances not yet been approved for human exposure, much
less consumption; nevertheless, the USDA rarely visits trial sites
more than once, and sometimes not at all. They have asked biopharmaceutical
companies to voluntarily comply with regulations a risky
proposition in any situation, and completely unacceptable in one
with such potentially dire consequences. Moreover, because of the
companies' desire to protect "confidential business information,"
total secrecy is the norm; crops are unidentified, unsecured, and
uncontained, camouflaged by their anonymity.
The soybeans in Nebraska and Iowa were
contaminated with a biopharmaceutical corn engineered by ProdiGene,
a Texas-based corporation whose vice president of product development
once boasted of a vaccine-producing corn that it was "right
by the interstate, and no on could ever have seen it." The
USDA previously denied Freedom of Information Act requests for documentation
of ProdiGene's trials, but it is known that they are experimenting
with a number of substances including a blood clotter, an
AIDS vaccine, a digestive enzyme, and an industrial adhesive
associated with severely adverse health effects. The FDA has refused
to identify the contaminating substance, saying only that it is
a "genetically modified material" not yet been approved
for human testing.
Although the FDA and USDA managed to
contain the spread of ProdiGene's corn, their public response betrayed
a failure to understand the gravity of the situation. Though the
"genetically modified material" was only a step away from
entering the nation's food supply, one senior USDA official merely
stated that "the department may consider revising its rules
to lessen the chance of similar problems in the future." Meanwhile,
the Biotech Industry Organization (BIO) has endorsed a moratorium
on the open-field testing of biopharmaceutical corn in the nation's
agricultural heartland, while the traditionally pro-biotech food
processing industry, fearful of losing export markets, has proposed
the restriction of biopharmaceuticals to non-food crops such as
tobacco. Neither of these measures is sufficient to address the
enormous scope of current industry and regulatory irresponsibility.
Because the public will bear the true
costs of mistakes made with biopharmaceutical crops, they have a
right to know exactly what is being done and to demand its effective
regulation. Until the USDA has publicly documented every single
biopharm trial in the nation, developed a system to guarantee the
containment of genetically modified crops, and worked with the FDA
to create a strong, enforceable, regulatory framework, the Council
for Responsible Genetics calls for a total moratorium on all open-field
biopharmaceutical trials. Furthermore, the open-field testing of
plants which produce unapproved substances should be permanently
banned.
The contaminations in Nebraska and Iowa
are a clear warning. Unless the biopharmaceutical industry is curbed,
it is only a matter of time before people are hurt. No commercial
gain is worth the risk that is now being taken, without our permission,
with us.
|